Conditions: Schizophrenia
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 4
Healthy volunteers: no

Brief summary:
The primary purpose of this study is to determine whether SPD489 40 mg, 100 mg, and 160 mg are effective and safe in the treatment of Negative Symptoms of Schizophrenia (NSS).

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None arm 4: None

Interventions: intervention 1: SPD489 40mg intervention 2: SPD489 100mg intervention 3: SPD489 160mg intervention 4: Placebo
Intervention descriptions: intervention 1: Oral administration of 40 mg once-daily for up to 12 weeks intervention 2: Oral administration of 100 mg once-daily for up to 12 weeks intervention 3: Oral administration of 160 mg once-daily for up to 12 weeks intervention 4: Oral administration once-daily for 12 weeks

Protocol document: